Alnylam Pharmaceuticals, Inc., 10% Owner at Regulus Therapeutics Inc. (RGLS), sold 113,084 shares at $14.90 ($1.6M) on 2014-10-23, disclosed to the SEC on 2014-10-28.
Scheduled sale ($1.6M) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.18 | 9,283 | $113K | 7.1% |
| 2 | $12.83 | 15,791 | $203K | 12.8% |
| 3 | $13.91 | 57,753 | $803K | 50.7% |
| 4 | $14.67 | 15,156 | $222K | 14.0% |
| 5 | $16.59 | 11,376 | $189K | 11.9% |
| 6 | $17.11 | 175 |
| $3K |
| 0.2% |
| 7 | $13.94 | 1,200 | $17K | 1.1% |
| 8 | $14.90 | 450 | $7K | 0.4% |
| 9 | $15.45 | 50 | $773 | 0.0% |
| 10 | $14.63 | 1,054 | $15K | 1.0% |
| 11 | $15.50 | 350 | $5K | 0.3% |
| 12 | $16.29 | 446 | $7K | 0.5% |
| Total | $14.02 avg | 113,084 | $1.6M | 100% |
| Filing → |
| RGLS | SELL | 2014-10-17 | $81K | — | Filing → |
| RGLS | SELL | 2014-10-10 | $66K | — | Filing → |
| RGLS | SELL | 2014-10-03 | $69K | — | Filing → |